A Nonadjuvanted Whole-Inactivated Pneumococcal Vaccine Induces Multiserotype Opsonophagocytic Responses Mediated by Noncapsule-Specific Antibodies

Shannon C. David, Erin B. Brazel, Eve V. Singleton, Vikrant Minhas, Zoe Laan, Catherine Scougall, Austen Y. Chen, Hui Wang, Chloe J. Gates, Kimberley T. McLean, Jeremy S. Brown, Giuseppe Ercoli, Rachel A. Higgins, Paul V. Licciardi, Kim Mulholland, Justin B. Davies, Timothy R. Hirst, James C. Paton, Mohammed Alshari

ABSTRACT  Streptococcus pneumoniae (Spn) remains a major cause of global mortality, with extensive antigenic diversity between capsular serotypes that poses an ongoing challenge for vaccine development. Widespread use of pneumococcal conjugate vaccines (PCVs) targeting Spn capsules has greatly reduced infections by vaccine-included serotypes but has led to increased infections by nonincluded serotypes. To date, high cost of PCVs has also limited their usefulness in low-income regions where disease burdens are highest. To overcome these limitations, serotype-independent vaccines are being actively researched. We have developed a whole-cell gamma-irradiated Spn vaccine (termed Gamma-PN) providing serotype-independent protection. We demonstrate that Gamma-PN immunization of mice or rabbits via the clinically relevant intramuscular route induces protein-specific antibodies able to bind numerous non-vaccine encapsulated serotypes, which mediate opsonophagocytic killing and protection against lethal challenges. Gamma-PN induced comparable or superior opsonophagocytic killing assay (OPKA) responses in rabbits to the licensed Prevnar 13 vaccine (PCV13) for vaccine-included serotypes, and a superior response to nonincluded serotypes, including emergent 22F and 35B. Additionally, despite a lower observed reactogenicity, administration of Gamma-PN without adjuvant resulted in higher OPKA responses and improved protection compared to adjuvanted Gamma-PN. To our knowledge, this has not been demonstrated previously for a whole-inactivated Spn vaccine. Eliminating the requirement for adjuvant comes with numerous benefits for clinical applications of this vaccine and poses interesting questions for the inclusion of adjuvant in similar vaccines in development.

IMPORTANCE  The target pathogen of this study, Streptococcus pneumoniae, kills over 300,000 children <5 years of age every single year, and is the leading cause of pneumonia-associated mortality globally. While the capsular polysaccharide (CPS)-based vaccine Prevnar13 prevents serious illness caused by 13 serotypes, ongoing Prevnar13 use has driven the emergence of nonincluded serotypes as major causes of infection and disease. To overcome this issue, we have developed a next-generation pneumococcal vaccine conferring serotype-independent protection. This vaccine shows equivalent or superior efficacy to Prevnar13, and performance was heightened when our vaccine was administered with no adjuvant. These findings should be considered for similar vaccines in development, as the benefit of adjuvant is often assumed and its automatic inclusion may be limiting product efficacy, resulting in potential abandonment of viable vaccine candidates, or prolonging their time to clinic.
**KEYWORDS** Streptococcus pneumoniae, adjuvants, in vivo protection, inactivated whole-cell vaccine, serotype independent protection, opsonophagocytic response, vaccines

*S. pneumoniae* (Spn) is an encapsulated diplococcus forming part of the commensal microbiome in the human nasopharynx. Carriage is typically asymptomatic, although Spn can translocate to other body sites to cause pneumonia and other invasive pneumococcal diseases (IPD). A recent review concluded Spn remains the most common cause of community-acquired pneumonia and is the most frequently isolated pathogen from patients with recurrent pneumonia (1). Spn is also notorious for causing secondary infection in patients with respiratory viral infections, leading to more severe disease and heightened mortality. While not explicitly linked to Spn, secondary bacterial infection of COVID patients was identified as a strong predictor of death (2).

Spn is classified into antigenically distinct serotypes based on the chemical structure of the capsule, with 100 unique serotypes currently identified (3). Capsular polysaccharides (CPS) are a major Spn virulence factor and are the primary antigen targets for current pneumococcal conjugate vaccines (PCVs). While effective, PCVs cover a limited selection of serotypes (e.g., 13 serotypes covered by PCV13, 20 serotypes by the newly licensed PCV20). This has led to rapid serotype replacement in multiple regions (4–6), with many emerging serotypes also being antibiotic-resistant (7–10). Indeed, the 3rd, 4th, and 5th most prevalent serotypes responsible for IPD in the US are not covered by PCV20, rendering the vaccine of limited utility. Furthermore, Spn serotype switching can occur via genetic transfer of capsule-related genes. Almost all Spn genes necessary for capsule biosynthesis are contained in a genetic cassette (*cps*), and a new Spn strain may arise after capturing genetic material from a nonvaccine Spn strain or a related species like oral streptococci (11). Indeed, analysis of the 100th unique serotype, 10D (Ganaie et al. [3]) provided compelling evidence for interspecies genetic transfer of *cps* from oral streptococci to pneumococci. Since oral streptococci have a large repertoire of *cps* loci, ongoing usage of capsule-specific Spn vaccines could drive emergence of more novel Spn serotypes through interspecies recombination.

These pressing issues paired with the cost and complexity of PCV manufacture have led to the pursuit of alternative vaccine strategies, including protein and whole-cell vaccine (WCV) candidates. WCVs present an appealing solution as they can be relatively inexpensively manufactured and present an almost complete range of Spn antigens in native conformation to the recipient's immune system. Redundancy of protein expression increases the likelihood that WCV-induced responses are reactive against a multitude of pneumococcal strains regardless of capsular type, isolation site, and genetic background. It has also been shown that naturally acquired protection against IPD largely depends on antibodies against protein antigens rather than capsule in mice (12) and humans (13). The WCV approach has been pursued by several groups using live-attenuated bacteria (12, 14), bacterial lysates (15), or inactivated whole-cell preparations (16–20).

Our prior studies detailed the development (18) and optimization (20) of a WCV comprising unencapsulated Spn bacteria inactivated by gamma irradiation (Gamma-PN). These prior studies demonstrated protection after intranasal immunization with no requirement for a mucosal adjuvant (18, 21). However, given that aluminum-based adjuvants are widely used in commercial vaccines, including PCV13, we sought to investigate the effect of an approved adjuvant on Gamma-PN efficacy. The intramuscular (IM) route was utilized in this study to investigate the effect of aluminum hydroxide adjuvant (Alhydrogel), and to investigate noninferiority of Gamma-PN (as a WCV) compared to the CPS-based PCV13.

**RESULTS**

Nonadjuvanted Gamma-PN shows high protective efficacy against Spn challenge. The Gamma-PN vaccine is derived from the unencapsulated Rx1 strain previously modified to delete the autolysin (lytA) gene and attenuate the pneumolysin (ply)
gene (detailed in Babb et al. [18]), and to delete the pneumococcal surface antigen A (psaA) gene (detailed in David et al. [20]); this strain was then inactivated by gamma irradiation (see Materials and Methods). Initially, we sought to demonstrate noninferiority of Gamma-PN against PCV13 for protection against lethal Spn challenges. Mice were immunized intramuscularly (IM) with three doses of either PCV13, Gamma-PN alone, or Gamma-PN in combination with the adjuvant Alhydrogel (Gamma-PN+Al), then challenged IN with Spn serotypes 3, 6A, or 22F (all heterologous serotypes to the ancestor of Gamma-PN). Fig 1A demonstrates Gamma-PN alone and Gamma-PN+Al were equivalent to PCV13 for protection against challenge with the highly encapsulated serotype 3, with all vaccines inducing significant protection compared to phosphate-buffered saline (PBS) mock controls. The second PCV13-included serotype, 6A (Fig. 1B) showed similar protection rates between Gamma-PN alone and PCV13, with survival rates of 50% and 70%, respectively (no significant difference by Fisher Exact test or Mann-Whitney U-test). Interestingly, however, IM vaccination with Gamma-PN+Al conferred significant protection against serotype 6A in terms of survival time, but not survival percentage (survival not significantly higher than PBS mock controls). The lower efficacy of Gamma-PN+Al relative to Gamma-PN alone was further apparent when mice were challenged with serotype 22F (Fig. 1C), as only Gamma-PN alone afforded a significant increase in survival time compared to PBS mock controls. Importantly, nonadjuvanted Gamma-PN was significantly more effective than PCV13 for protection against this non-PCV13 serotype.

**Adjuvant increases reactogenicity at the injection site.** It is well-known that aluminum-containing adjuvants induce inflammation at the injection site, leading to recruitment of antigen-presenting cells. As the addition of adjuvant to Gamma-PN had some effects on protective efficacy, it became important to address the impact of adjuvant on inflammatory responses. To investigate the kinetics of innate immune cell influx, mice were IM immunized once with Gamma-PN, Gamma-PN+Al, or PCV13, and muscle samples were harvested 6 to 72 h postvaccination for histology and cytokine analyses. These time points were chosen based on previous studies reporting local edema and infiltration of neutrophils at 24 to 72 h after IM injection of similarly adjuvanted vaccines (22, 23), with appearance of monocytes and dendritic cell precursors by 72 h (24). Hematoxylin and eosin staining revealed rapid inflammatory responses in muscles injected with Gamma-PN+Al, indicated by infiltration of polymorphonuclear leukocytes by 24 h postimmunization (Fig. 2A). Pockets of densely populated nucleated cells were visible in muscles injected with Gamma-PN+Al and with PBS+Al (control), while nucleated cells in muscles treated with Gamma-PN and PCV13 were far less dense and more evenly dispersed throughout the tissue. Additionally, some necrosis of myocytes was visible in muscles injected with Gamma-PN+Al and PBS+Al (indicated by the thinning/waving of muscle fibers and an increase in intercellular spaces), suggesting muscle damage in these groups.

To further investigate the innate immune landscape at the injection site, muscle homogenates were analyzed by cytokine multiplex assay (Crux Biolabs, Melbourne, Australia). Fig 2B shows vaccination with Gamma-PN+Al induced the most pronounced and prolonged inflammatory state of the five groups. As early as 6 h postvaccination, Gamma-PN+Al induced significantly elevated levels of inflammatory cytokines GM-CSF, IL-6, and MIP-1α compared to Gamma-PN only or control groups. Additional cytokines G-CSF, IL-1β, MCP-1, MCP-3, MIP-1β, and MIP-2 were comparable between the Gamma-PN and Gamma-PN+Al groups at 6 h but remained elevated in the Gamma-PN+Al group only for the full-time course. This is partially attributed to adjuvant, as PBS+Al controls showed increasing levels of inflammatory mediators MCP-1, MCP-3, and MIP-1β with time. The cytokine profile of Gamma-PN alone largely resembled that of PCV13 at 24 and 48 h, except for MCP-3 and MIP-1β, which were higher in Gamma-PN treated mice at 24 h.

**Adjuvant alters serum IgG subclass profiles in mice.** Gamma-PN+Al appeared to induce higher reactogenicity, but lower protection rates compared to Gamma-PN alone and PCV13. This suggested adjuvant was interfering with induction of adaptive
responses against Spn, namely, humoral immunity. To investigate the effect of adjuvant on Gamma-PN-specific antibodies, mice were immunized IM three times with Gamma-PN alone or Gamma-PN+Al. Mice were also immunized with Gamma-PN via the intranasal (IN) route as an additional control. Immune sera were harvested from all mice after the 3rd immunization, and total IgG titers and the relative abundance of murine IgG subclasses (IgG1, IgG2a, IgG2b, and IgG3) were determined by ELISA. Total IgG titers were comparable when Gamma-PN was administered via IN and IM routes without adjuvant, indicating the choice of parenteral or mucosal immunization route did not negatively affect antibody responses (Fig. 3A). As anticipated, the addition of
FIG 2  Analysis of inflammatory responses at the immunization site. Swiss mice were vaccinated IM with Gamma-PN alone or Gamma-PN+AI (25 μg of Gamma-PN/dose in both cases), or the commercially available PCV13 vaccine. Control mice received (Continued on next page)
adjuvant to IM-administered Gamma-PN (Gamma-PN+Al) resulted in a substantial increase in serum IgG, and a marked difference in IgG subclass profiles (Fig. 3B and C). Spn-specific IgG1 and IgG2b were enhanced by adjuvant, while IgG2a was somewhat reduced. IgG3 did not appear to be affected. Importantly, the addition of adjuvant altered these subclass ratios, with the ratio of IgG1:IgG2a and IgG1:IgG3 being higher in Gamma-PN+Al immunized mice compared to Gamma-PN alone (see Table S3 in Supplemental Material). This suggests an adjuvant-mediated shift toward Th2-type immunity which favors IgG1 over other subclasses.

**Gamma-PN induces cross-reactive antibodies against Spn proteins in mice.** The ability of Gamma-PN-induced antibodies to bind whole-encapsulated Spn bacteria was then assessed using flow cytometry. Immune sera from mice immunized with PCV13 were also included here to compare functionality of WCV-induced antibodies to those induced by the CPS-based PCV13. Multiple serotypes of live encapsulated Spn were incubated with immune sera, then incubated with a fluorescein isothiocyanate (FITC)-conjugated antimurine IgG antibody and analyzed for IgG binding by flow cytometry.

Fig 3D shows comparable binding by sera from animals vaccinated with Gamma-PN alone by IN and IM routes, again indicating Gamma-PN was just as immunogenic when administered IM. Furthermore, Gamma-PN-induced antibodies were more effective than PCV13-induced antibodies against non-PCV13 serotypes 2, 22F, and 35B. Conversely, PCV13-induced antibodies showed superior binding to highly encapsulated serotype 3. It is worth noting that immunization with Gamma-PN induced comparable protection against serotype 3 during challenge despite this large disparity in Spn binding, indicating that non-CPS-specific antibodies induced by Gamma-PN are as effective as PCV13-induced CPS-specific antibodies for in vivo protection. Interestingly, sera from animals vaccinated with Gamma-PN+Al did not show improved binding in these assays. In fact, sera from mice vaccinated IM with Gamma-PN alone showed significantly higher binding to serotypes 22F and 35B compared to Gamma-PN+Al, despite the significant increase in total IgG for mice receiving the adjuvanted vaccine. Antibody reactivity to conserved Spn proteins was then assessed by Western blotting (Fig. 3E), with whole-cell lysates from a panel of Spn serotypes probed using pooled Gamma-PN or Gamma-PN+Al immune sera. Banding profiles were relatively similar between vaccine groups.

**Gamma-PN induces high-titer IgG with broad reactivity to Spn proteins in rabbits.** The observed decrease in antibody functionality and protective efficacy when Gamma-PN was adjuvanted in mice was unexpected. Thus, rabbits were utilized as a second animal model to ensure these differences were not a mouse-specific anomaly. Rabbits were IM immunized with PCV13, Gamma-PN, or Gamma-PN+Al. Sera were harvested from all animals after the 3rd immunization. Rabbits were also bled prior to immunizations, with pooled prevaccination sera used as a baseline control. ELISA was initially used to determine whether adjuvant could increase the magnitude of Gamma-PN-induced antibody responses in rabbits. Fig 4A shows that baseline titers of Spn-specific IgG in individual preimmune samples fluctuated between 125 and 600, which was expected due to the use of outbred rabbits. After Gamma-PN immunization, 10- to 100-fold increases in IgG levels were observed for all animals, with calculated titers between 10,000 and 50,000 for individual rabbits. Data also show that adding adjuvant...
FIG 3 The effect of adjuvant on IgG antibody responses after Gamma-PN immunization of mice. Swiss mice were vaccinated IM with Gamma-PN or Gamma-PN + Alhydrogel (+ Al) (25 μg Gamma-PN/dose in both cases). For IN vaccination, animals received 25 μg of Gamma-PN alone (no Al). Control mice (Continued on next page)
to Gamma-PN did not significantly enhance IgG titers, instead appearing to slightly dampen total titers compared to Gamma-PN alone (Fig. 4B). As expected, PCV13-induced antibodies showed baseline reactivity against the nonencapsulated Gamma-PN vaccine that was used as coating antigen.

Pooled immune sera from each vaccine group (n = 2 to 4 rabbits per group) were then used to probe Western blots of whole-cell lysates of a panel of PCV13-included and nonincluded serotypes. Fig 4C shows rabbit antibodies induced by Gamma-PN had a high level of reactivity to protein antigens present in all serotypes tested. Importantly, a prominent difference in the immunodominant protein bands bound by sera from Gamma-PN and Gamma-PN+Al immunized rabbits was now observed. To gain additional information on the range of antigens bound by each immune serum type, a protein microarray of 289 purified Spn antigens was probed with Gamma-PN- or Gamma-PN+Al-immune sera. Spn proteins showing significant antibody reactivity were ranked according to mean fluorescence intensity (MFI), and the top 50 protein hits are presented in Table 1. Prebleed sera showed minimal reactivity to all 50 of these antigens. This protein array was previously used to probe antibody responses to Spn proteins in mice (12, 25), and our data show reactivity to a considerably larger number of Spn proteins for Gamma-PN-immunized rabbits compared to prior studies. Interestingly, of the 50 top antigens, 11 fell below the threshold of detection when Gamma-PN was adjuvanted, supporting the notion of impaired antibody reactivity. Comparing log2 fold changes between adjuvanted and nonadjuvanted Gamma-PN also showed adjuvanted sera had decreased binding to almost all the top 50 protein hits, with the exception of LIVJ which showed a minor 1.2-fold increase in reactivity (Table 1). Antigens displaying >4-fold reduction in reactivity when Gamma-PN was adjuvanted were identified as: DnaK, Pbp1A, ValS, MetE, SP_1394, PrtA, PotH, AliA, and SpxB. MFI for all antigens (i.e., total IgG binding) was also quantified as a measure of total protein reactivity; Fig. 4D shows serum from Gamma-PN-immunized rabbits had significantly stronger reactivity compared with rabbits receiving Gamma-PN+Al. Finally, pooled sera from Gamma-PN-vaccinated rabbits were found to confer significant passive protection to mice against Spn serotype 6A challenge, whereas prebleed sera and sera from Gamma-PN+Al-vaccinated rabbits offered no protection (Fig. 4E), suggesting the Spn proteins showing reduced antibody reactivity were also antigenically important for in vivo protection.

Antibodies induced by nonadjuvanted Gamma-PN are superior for encapsulated Spn binding. Binding assays were again performed to compare the performance of protein-specific antibodies induced by Gamma-PN to the CPS-specific antibodies induced by PCV13. Live Spn serotypes were incubated with pooled rabbit immune sera, then probed with a fluorophore-conjugated anti-IgG antibody for analysis by flow-cytometry. Fig. 5 shows rabbit antibodies induced by the nonencapsulated Gamma-PN were capable of recognizing protein targets on the surface of all capsular Spn serotypes tested. Note that high binding of capsule-specific antibodies present in

FIG 3 Legend (Continued)

received PBS+Al IM as a mock vaccine. All mice received 3 immunizations administered 2 weeks apart, and sera were harvested 1 week after the final immunization. (A) Total Spn-specific IgG in sera of immunized and control mice was determined by ELISA, using whole-cell Gamma-PN as coating antigen. Data presented as mean titers ± SD, and as mean absorbance values ± SD (n = 10 mice per group). Titters were calculated using nonlinear regression modeling and analyzed by one-way ANOVA (***, P < 0.001; **, P < 0.01; ns, not significant). (B) Absorbance values for the subclasses IgG1, IgG2a, IgG2b, and IgG3 for each IM immunization group were determined by ELISA, using Gamma-PN as coating antigen (n = 3 mice per group, mean absorbance ± SD is shown). (C) Relative serum titers for each IgG subclass are also presented (mean ± SD). Data generated from two independent experiments. ND, not detected. (D) Intact Spn strains of serotype 2, 3, 22F, and 35B were probed with harvested murine sera (pooled within each vaccine group, n = 10 mice per group), then washed and stained with antimurine IgG FITC-conjugated antibody. Pooled immune sera from mice (n = 10) immunized IM 3× with PCV13 was included as an additional binding control. All Spn samples were acquired on an Accuri flow cytometer, with a minimum of 10,000 events acquired per sample. Data are presented as FITC GMFI (mean ± SD) of un gated samples, and as percentage of the total bacterial population staining positive for IgG (mean ± SD) relative to unstained controls. Representative histograms for FITC fluorescence are also shown for serotypes 22F and 35B. Data are compiled from at least two independent flow cytometry experiments for all serotypes, with pooled sera tested in technical triplicate in each case. Data were analyzed by one-way ANOVA, with significance relative to PBS mock controls indicated on top of each column, and significance between vaccine groups indicated by horizontal lines (***, P < 0.0001; **, P < 0.001; *, P < 0.01; ns, not significant). (E) Reactivity of pooled murine sera from Gamma-PN or Gamma-PN+Al IM immunized mice was tested by Western Blot against whole-cell lysates of a range of Spn serotypes. Western blots are representative of two independent tests of pooled immune sera. Note that both blots were probed with immune sera at a set dilution of 1/1,000, hence all bands appeared more intense for the Gamma-PN+Al group due to the higher overall IgG titer.
PCV13-induced sera confirmed that capsule was present on the relevant Spn strains tested. Antibodies induced by Gamma-PN alone were equivalent or superior to PCV13-induced antibodies for binding to all tested serotypes, including the highly encapsulated serotype 3. This differs to data observed for murine antibody binding to serotype 3 (Fig. 3D), suggesting differences in species-specific vaccine processing and highlighting the importance of testing multiple animal models for vaccine efficacy. Immune sera from PCV13-vaccinated rabbits did show binding to the nonincluded serotype 6C.

**FIG 4** The effect of adjuvant on IgG antibody responses after Gamma-PN immunization of rabbits. Rabbits were immunized IM with PCV13, Gamma-PN, or Gamma-PN + Alhydrogel (+Al). All rabbits received three immunizations 3 weeks apart. Serum was taken from all rabbits prior to immunizations (prebleed), and again 3 weeks after the final immunization. Individual sera were tested for total IgG by ELISA, using whole-cell Gamma-PN as the capture antigen. Data presented as (A) IgG titers pre- and post-3rd immunization for each individual rabbit, and (B) mean IgG titers (±SD) within each vaccine group. IgG data were compiled from two independent experiments, and the difference between Gamma-PN groups was determined using one-way ANOVA. (C) Reactivity of pooled rabbit sera was tested by Western blot against whole-cell lysates of Spn serotypes. Western blots are representative of two independent tests of pooled immune sera. (D) Pooled sera were used to probe a microarray of purified Spn antigens printed on nitrocellulose coated glass AVID slides. Results are expressed as GMFI for total IgG binding in each group. Data analyzed by one-way ANOVA (***, P < 0.001; ****, P < 0.0001). Sera were pooled from two independent immunization experiments and tested in triplicate. (E) Survival time of mice IP-challenged with serotype 6A (10^4 CFU/mouse) that was pretreated with pooled prebleed rabbit sera or with pooled immune sera from Gamma-PN- or Gamma-PN + Al-immunized rabbits (sera pooled from two independent immunization experiments). Survival was monitored for 7 days postchallenge, and mice were humanely euthanized when they reached a moribund state. Survival percentages analyzed by Mantel-Cox test (*, P < 0.05; n = 5 mice per group).
| Antigen details | Mean fluorescence intensity ± SD | Log₂ fold change |
|-----------------|----------------------------------|------------------|
| **TABLE 1** IgG reactivity induced by immunization with nonadjuvanted and adjuvanted Gamma-PN against antigenic Spn proteins* | | |
| **SP**_0719 Membrane protein, putative | | |
| **SP**_0042 | | |
| **SP**_2099 | | |
| **SP**_0629 VanY domain-containing protein | 42,217.8 ± 1,122.67 | 37,093.93 ± 722.93 | 0.187 |
| **SP**_0366 | | |
| **SP**_0641 | | |
| **SP**_0568 | | |
| **valS** | | |
| **amiC** | | |
| **SP**_2239 Manganese ABC transporter substrate-binding lipoprotein | 32,985.13 | 1,904.6 | 0.066 |
| **SP**_0981 psrA | 25,497.93 | 918.93 | 0.038 |
| **SP**_0453 Amino acid ABC transporter, amino acid-binding protein/ permease protein | 27,537.6 | 927.66 | 0.036 |
| **SP**_2169 adcA Zinc-binding lipoprotein AdcA | 24,388.13 | 1,030.42 | 1.483 |
| **SP**_1032 piaA Iron-compound ABC transporter, iron compound-binding protein | 20,894.7 | 865.98 | 0.282 |
| **SP**_1128 eno Enolase | 23,680.47 | 1,947.58 | 0.022 |
| **SP**_0374 mapZ Midcell-anchored protein Z | 23,430.8 | 891.93 | 0.154 |
| **SP**_1891 amiA Oligopeptide-binding protein AmiA | 32,327.4 | 5,391.01 | 0.908 |
| **SP**_1942 Putative transcriptional regulator | 25,966.8 | 1,217.6 | 0.036 |
| **SP**_2218 mreC Cell shape-determining protein MreC | 23,055.47 | 1,714.05 | 0.763 |
| **SP**_1174 Conserved domain protein | 22,441.8 | 2,228.77 | 0.833 |
| **SP**_2239 htrA Serine protease | 22,424.13 | 2,703.81 | 0.020 |
| **SP**_2029 yajC-I Preprotein translocase, YajC subunit | 21,555.47 | 795.13 | 1.483 |
| **SP**_0568 valS Valine–tRNA ligase | 20,894.7 | 865.98 | 0.282 |
| **SP**_1479 pgdA Peptidoglycan N-acetylgalactosamine deacetylase A | 20,514.8 | 1,842.74 | 0.923 |
| **SP**_0629 vanT domain-containing protein | 17,791.3 | 1,923.57 | 1.193 |
| **SP**_0845 Lipoprotein | 17,436.8 | 1,509.69 | 0.116 |
| **SP**_0877 fraA PTS system, fructose specific IIABC components | 16,762.47 | 1,323.25 | 0.436 |
| **SP**_1368 psr Psr protein | 16,422.13 | 2,437.2 | 0.900 |
| **SP**_0730 spxB Pyruvate oxidase | 15,773.8 | 1,840.67 | 2.131 |
| **SP**_1872 piaA Iron-compound ABC transporter, iron compound-binding protein | 15,729.47 | 473.02 | 0.220 |
| **SP**_2108 malX MalT/maltose-binding protein | 15,613.47 | 1,742.34 | 0.653 |
| **SP**_2012 gap Glycerolaldehyde-3-phosphate dehydrogenase | 10,625.13 | 3,769.8 | 0.654 |
| **SP**_1890 amiC Oligopeptide transport system permease protein AmiC | 9,958.47 | 2,560.59 | 0.388 |
| **SP**_0369 pbp1A Penicillin-binding protein 1A | 8,312.8 | 1,701.7 | 2.131 |
| **SP**_0283 manM PTS system, mannose specific IIC component | 8,081.47 | 946.68 | 0.728 |
| **SP**_0149 Lipoprotein | 8,001.47 | 6,027.8 | 2.131 |
| **SP**_1650 psoA Manganese ABC transporter substrate-binding lipoprotein | 7,472.47 | 2,298.1 | 1.972 |
| **SP**_1388 potH Spermidine/putrescine ABC transporter, permease protein | 6,467.13 | 1,744.26 | 2.444 |
| **SP**_2085 pstC Phosphate transport system permease protein | 5,396.8 | 2,017.12 | 4.545 |
| **SP**_2084 manL ELAB-Man | 5,374.13 | 193.91 | 0.810 |
| **SP**_2223 hypothetical protein | 4,849.8 | 467.69 | 0.521 |
| **SP**_0807 ezcA Septation ring formation regulator EzczA | 4,522.8 | 1,316.05 | 0.000 |
| **SP**_0069 etxI Thioredoxin family protein | 4,332.8 | 1,408.67 | 0.515 |
| **SP**_0641 ptaA Serine protease, subtilase family | 4,042.47 | 451.63 | 2.581 |
| **SP**_0366 aliA Oligopeptide-binding protein AliA | 3,950.8 | 1,107.35 | 2.386 |
| **SP**_2099 pbp1B DD-transpeptidase | 3,867.8 | 445.11 | 1.574 |
| **SP**_0042 comA Transport process/ATP-binding protein ComA | 3,754.8 | 2,364.97 | 0.536 |
| **SP**_0719 membrane protein, putative | 3,754.47 | 149.46 | 0.501 |
| **SP**_0749 livJ Branched-chain amino acid ABC transporter, amino acid-binding protein | 3,063.13 | 332.5 | 1.165 |
| **SP**_0807 effA Phosphate-binding protein PstS 1 | 2,907.13 | 852.5 | 0.000 |
| **SP**_0585 metE 5-methyltetrahydropteroylglutamate–homocysteine methyltransferase | 2,759.47 | 1,408.23 | 119.73 ± 160.57 | 4.545 |

*Antigens are sorted based on the mean fluorescence intensity (MFI) of the nonadjuvanted Gamma-PN samples. The identity of each antigen is shown by TIGR4 locus tag, gene name (if known) and protein function. The relative IgG levels are shown by the log₂ fold change for the adjuvant versus no adjuvant Gamma-PN groups. Antigens with at least one replicate below the threshold of detection are shown in bold. Data presented as the mean fluorescence intensity ± SD of pooled sample from immunized rabbits (sera pooled from two independent vaccination experiments). Log₂ fold change calculated using MFI.
consistent with previously reported cross-reactivity among Spn serogroup 6 (26–28). Regardless, Gamma-PN-induced sera showed significantly higher FITC geometric mean fluorescence intensity (GMFI) than PCV13-induced sera when reacting with 6C, indicating a higher density of antibodies were bound to individual Spn cells. Furthermore, these data demonstrate stark differences in antibody functionality between the Gamma-PN and Gamma-PN+Al groups. FITC GMFI and total percentages of IgG-bound cells were both significantly lower when probing Spn with sera from rabbits receiving adjuvanted Gamma-PN compared to the nonadjuvanted counterpart. This occurred for every Spn serotype tested, and unequivocally demonstrates that antibody reactivity was negatively affected by formulation of this WCV with adjuvant.

Nonadjuvanted Gamma-PN induces OPKA responses against PCV13-included and nonincluded serotypes. Vaccine performance was next compared using the opsonophagocytic killing assay (OPKA), which has been standardized using differentiated HL-60 cells (29–32) and is considered a gold-standard assay to test the potential clinical efficacy of new Spn vaccines. Individual rabbit sera (taken after the final immunization with Gamma-PN, Gamma-PN+Al, or PCV13) were tested using the established

**FIG 5** Encapsulated Spn binding by sera from Gamma-PN- and PCV13-immunized rabbits. Rabbits were immunized IM with PCV13, Gamma-PN alone, or Gamma-PN+Al (0.5 mg Gamma-PN/dose in each case). All rabbits received three immunizations 3 weeks apart. Serum was taken from all rabbits 3 weeks after the final immunization and pooled within each immunization group (n = 2 to 4 rabbits per group per experiment). Pooled sera were tested for IgG binding to encapsulated Spn using flow cytometry. Serum was also harvested from all rabbits prior to any immunizations and pooled in equal volumes as a baseline control for nonspecific binding (terming prebleed [Pre-Bl], with 8 rabbit samples total pooled per experiment). Pooled immune sera and prebleed samples were then tested in technical triplicate for flow cytometry experiments against (A) PCV13-included serotypes, or (B) non-PCV13 serotypes. Histograms are representative of two independent immunization experiments, with subsequent analysis by independent flow cytometry experiments. Data for GMFI and percentage of positive cells are compiled from both independent sets of experiments, and are presented as mean ± SD. Quantitative data were analyzed by one-way ANOVA (significance compared to prebleed control is indicated on top of each column, and significance between vaccine groups is indicated by horizontal lines; ***, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05; ns, not significant).
Spn killing mediated by pooled prebleed sera was also tested. The Opsotiter 3 program (kindly provided by Robert L. Burton, UAB) was used to calculate the precise reciprocal of serum dilution where 50% killing of the input CFU titer was reached, also termed the opsonic index (OI). Geometric mean OI values for each vaccine group (\(n = 3\) to 6 rabbits per group) are listed in Table 2. These data show Gamma-PN with no adjuvant was comparable or superior to PCV13 in mediating opsonophagocytic killing against PCV13-included serotypes 6A and 23F, and more effective than PCV13 against nonincluded serotypes 9N, 11A, 15A, 22F, 23B, 33F, and 35B. Additionally, mixing Gamma-PN with adjuvant reduced opsonophagocytic killing against most of these tested serotypes.

OPKA results were externally validated by a third-party laboratory (New Vaccines Laboratory, Murdoch Children’s Research Institute). OPKA data were generated for serotype 6A (PCV13-included) and 22F (nonincluded) and are shown in Fig. 6. These data confirm nonadjuvanted Gamma-PN was significantly more effective in mediating opsonophagocytic killing of encapsulated Spn for a PCV13-included and a nonincluded serotype. Gamma-PN was able to mediate >90% killing of input CFU across all tested serum dilutions, and yielded OI values >8,748 against serotypes 6A and 22F. Comparatively, PCV13 returned OI values of 622 and 19 in the same assay. Pooled human reference sera from 287 participants receiving Pneumovax 23 (007sp) was also included in these OPKA validations and showed high levels of killing against the 6A and 22F serotypes. This was expected as serotype 22F is included in the composition of Pneumovax 23, and while 6A is not explicitly included, the closely related 6B is present and cross-reactivity between serogroup 6 has been reported previously. Human subjects may have also been naturally exposed to 6A prior to sera collection, with IgG analysis showing the presence of anti-6A IgG within 007sp (33). Despite high reactivity of the 007sp human reference sera, Gamma-PN-immune sera were superior in these external assays.

## DISCUSSION

Spn is a major human pathogen that continues to cause >1 million deaths annually, particularly in young children and the elderly. Current vaccines cover a limited
range of Spn serotypes and are unable to protect against emerging nonvaccine serotypes and unencapsulated isolates. This has led to serotype replacement in multiple regions (4–6) with many antibiotic-resistant nonvaccine serotypes (7–10). Hence, there is an urgent need for new strategies to induce serotype-independent immunity that are also globally accessible.

This study details the efficacy of Gamma-PN as a serotype-independent Spn WCV and demonstrates noninferiority to PCV13 for protection against challenge (Fig. 1), binding to encapsulated Spn (Fig. 5), and OPKA responses (Fig. 6, Table 2) against PCV13-included and nonincluded serotypes. Additionally, adjuvant was not required for induction of significant protection by Gamma-PN against tested Spn isolates (heavily encapsulated serotype 3, serotype 6A, and a human isolate of 22F), and inclusion of adjuvant actively reduced Gamma-PN-induced antibody functionality in rabbits and mice. The effect was most pronounced in rabbits, where Alhydrogel failed to increase IgG titers in serum, and significantly decreased antibody functionality when assessed by protein microarray (Fig. 4D, Table 1), passive protection assay (Fig. 4E), Spn binding assays (Fig. 5), and OPKA (Table 2). Adding adjuvant to Gamma-PN also increased local inflammation at the immunization site (Fig. 2), with no apparent benefit to vaccine performance.

This finding distinguishes Gamma-PN from Spn vaccines developed by other groups. For example, Malley and colleagues (16, 17, 34) developed a similar Spn vaccine (RM200) and have reported phase 2 trials (ClinicalTrials.gov Identifier: NCT02097472). RM200 is chemically inactivated, and murine studies showed protective efficacy relied on administration with cholera toxin-based adjuvants (16, 17), or aluminum hydroxide as adjuvant (34). Meta-analysis highlighted that the majority of other whole-inactivated Spn vaccines in the literature also require coadministration with adjuvant for protective efficacy (35).

A small number of adjuvants are currently licensed for human use, with aluminum hydroxide (e.g., Alhydrogel [AH]) and aluminum phosphate (e.g., AdjuPhos [AP]) being the most commonly used (36), including in the commercially available PCV13. Alhydrogel was selected for this study as a representative aluminum-based adjuvant. Both AH and AP have large adsorptive surfaces, with adsorption of antigens intended to increase retention at the injection site. Aluminum-based adjuvants are also associated with recruitment of macrophages, dendritic cells, neutrophils, and eosinophils to the injection site in a time-dependent manner (37) and a Th2 bias with a marked

---

**FIG 6** External validation that nonadjuvanted Gamma-PN induces superior OPKA responses against a PCV13-included (6A) and nonincluded serotype (22F). Rabbits were immunized IM with PCV13 or nonadjuvanted Gamma-PN (GPN). All rabbits received 3 immunizations 3 weeks apart, and sera were harvested 3 weeks after the final immunization. Pooled immune serum samples (n = 3 for PCV13, n = 6 for Gamma-PN) were titrated using OPKA by a third-party laboratory. Pooled human reference sera from the Pneumovax23 clinical trial was also tested (007sp). Titration curves show the percentage of input CFU recovered after OPKA with serially diluted sera. The dashed line in each panel represents 50% recovery of the input CFU (i.e., 50% killing), and the solid line indicates 100% recovery (i.e., 0% killing) relative to no sera controls. Pooled sera were tested in technical duplicate, and individual data points indicate the mean ± SD of CFU recovered at each serum dilution. Data were generated by external laboratory New Vaccines, MCRI. Data indicate results of a single OPKA experiment.
increase in IL-4-secreting CD4+ T cells (38). Consistent with this, we observed a bias toward Th2-type IgG subclasses here when Gamma-PN was adjuvanted (Fig. 3). Importantly, this also caused unexpected detrimental effects on antibody functionality and protective efficacy.

Strong adsorption of soluble antigens to AH particles is known to increase antigen uptake by DC's (39), though overly strong interactions may negatively affect the structural stability of antigens and interfere with epitope availability for proteolytic processing and binding by MHC-II molecules (40, 41). High adsorptive capacity of AH is associated with poor antigen elution and can interfere with antibody production and T-cell activation in response to injection of soluble proteins (42). Additionally, Hogenesch et al. (43) demonstrated AH has a high adsorptive capacity for whole-cell Spn. Authors postulated that strong antigen adsorption may be less detrimental to immune responses against whole bacteria, as this antigen type is ~1 µm in diameter while adjuvant particles are <50 nm (44). However, high-affinity adsorption of AH to soluble or membrane-bound Spn proteins is likely to have detrimental effects on antigen processing, potentially masking epitopes from immune recognition and interfering with MHC-II presentation. In line with this, reduced antibody reactivity to many Spn proteins was observed when Alhydrogel was used to adjuvant Gamma-PN (Table 1).

The surface charge of AH is also positive at neutral pH, resulting in differing affinities for antigens that adsorb via electrostatic interactions (44). Spn is typically considered to have a net negative charge due to capsular polysaccharides (45, 46), with cell-surface structures (e.g., choline-binding proteins) also contributing (47). Purified Spn proteins pneumococcal surface antigen A (PsaA) and serine-threonine protein kinase (StkP) adsorb to a greater degree to AH than to AP, indicating negative charge of these soluble proteins (48). Whole-cell Rx1 is also reported to have a similar electronegative charge to the parent strain D39 (47), suggesting removal of capsule does not dramatically alter the net charge of serotype 2 Spn. It can therefore be inferred that the unencapsulated Gamma-PN (also derived from the D39 descendant Rx1) would be highly negatively charged and would readily adsorb to positively charged AH.

Antigens additionally adsorb to aluminum adjuvants via ligand exchange, where surface hydroxyls are replaced by terminal phosphate groups of phosphorylated antigens, creating a covalent bond. AH has many surface hydroxyls and thus has very high affinity for phosphorylated antigens (44). Viral vaccine studies have reported correlations between increased adsorption of phosphorylated proteins and decreased immunogenicity (42, 49, 50). Spn proteins PcpA, PhtD, and Ply strongly bind AH due to ligand exchange, with AH adsorption being additionally associated with decreased protein stability during long-term incubation (51). Thus, excessively high binding of whole-cell Spn and/or soluble protein components by AH adjuvant is likely to occur via both electrostatic interaction and ligand exchange, and the aforementioned studies link this high adsorption to reduced vaccine immunogenicity.

The negative influence of Alhydrogel on Gamma-PN-induced antibodies could additionally be related to a biased IgG subclass profile. While the propensity of adjuvants to bias immunity along a Th2-type pathway is recognized to enhance total antibody production, the effect on antibody functionality must be given equal consideration. For Gamma-PN+Al-immunized mice, IgG1 was the predominant subclass, indicative of a classic Th2-type response. Conversely, IgG1 was more proportionate to other subclasses for mice immunized with Gamma-PN alone (Table S3), indicating a more balanced Th1/Th2-type response. IgG1 antibodies can neutralize toxins and viruses through steric hindrance, but they are reported to be ineffective in complement fixation and for triggering FcγR-mediated effector functions. In contrast, IgG2a and IgG2b are substantially better at fixing complement, and for Fc receptor binding and associated phagocytic functions (52–56). A broader Th1-skewed subclass distribution would therefore be beneficial against Spn, and potential saturation with the suboptimal IgG1 seen for Gamma-PN+Al-immunized mice could explain disparities in antibody titer and protective efficacy.
Detrimental effects of Th2-skewed responses have been reported before. Jang et al. (14) developed an Spn vaccine comprised of TIGR4 deficient in lipoprotein diacylglycercyl transferase (lgt) and subsequently inactivated with gamma irradiation, similar to Gamma-PN. However, the killed TIGR4 vaccine induced less effective protection against Spn challenge and less IFN-γ production by splenocytes compared to the live Δlgt Spn vaccine counterpart, which was attributed to the vaccine inactivation method shifting the IgG subclass profile to be IgG1-dominated (14). It is worth noting the TIGR4 vaccine was treated with 5 kGy of gamma irradiation at room temperature, which may not be sufficient to reach a sterility assurance level of 10⁻⁶, whereas Gamma-PN is irradiated with higher doses while frozen on dry-ice for better maintenance of antigen integrity (57). Investigation of a group A Streptococcus vaccine also showed Alhydrogel induced Th2-type IgG subclass profiles, and negatively affected protection rates compared to other adjuvants (58). Note that no comparison was made to the vaccine alone, though adjuvants associated with better protection also induced more balanced Th1/Th2 responses.

Importantly, other killed whole-cell Spn preparations have been reported to induce minimal OPKA responses in animals after IN (19) or SC immunization (59), and the RM200 vaccine did not produce detectable OPKA responses in humans after adjuvanted vaccination (60). Here, OPKA responses for nonadjuvanted Gamma-PN were similar in efficacy to PCV13-induced responses against PCV13-included serotypes, with Gamma-PN also outperforming PCV13 against the included serotype 6A. Nonadjuvanted Gamma-PN was then superior to PCV13 for opsonophagocytic killing against 8 different non-PCV13 serotypes, including the emergent serotypes 22F, 33F, and 35B. Higher OPKA efficacy of Gamma-PN compared to PCV13 against serotypes 6A and 22F was also externally validated (Fig. 6). As Gamma-PN lacks CPS, the antibodies mediating OPKA responses are presumably largely protein-specific. Experimental pneumococcal vaccines comprising various purified protein antigens have been under study for decades, but to our knowledge, none of these have been shown to elicit a significant OPKA response. The likely explanation for the strong OPKA responses observed in the present study is the breadth and strength of the antiprotein response elicited by Gamma-PN, as shown in Table 1. This enables a much larger total amount of IgG to be bound to the surface of encapsulated pneumococci than can be achieved when just a few protein species are targeted. Indeed, our flow cytometry data (Fig. 5) showed that total IgG binding using Gamma-PN serum matched or exceeded binding achieved using the CPS-specific PCV13 serum for several vaccine-included serotypes. A further point of significance is that unlike CPS-specific antibodies elicited by PCV13, the antiprotein responses elicited by Gamma-PN have the potential to neutralize the biological activities of many of their protein targets. Blockade of surface protein function, which may be critical for pathogenesis, may have contributed to the strong protection against challenge with type 3 Spn seen in Fig. 1, despite a weaker OPKA response relative to PCV13 for this particular serotype.

Overall, this study demonstrates the efficacy and clinical suitability of the WCV Gamma-PN. To our knowledge, no study has demonstrated superior efficacy of a nonadjuvanted whole-inactivated Spn vaccine, either when tested against its own adjuvanted counterpart or against the licensed PCV13. We conclude Gamma-PN is well-suited for clinical evaluation without the need for an adjuvant, which brings many cost and tolerability benefits in addition to the immune-specific benefits observed here.

MATERIALS AND METHODS

Ethics statement. Animal experimentation was conducted in strict accordance with the Australian Code of Practice for Care and Use of Animals for Scientific Purposes (7th edition [2004] and 8th edition [2013]) and the South Australian Animal Welfare Act 1985. Murine experimental protocols were approved by the Animal Ethics Committee at The University of Adelaide (Approval number S-2016-183). Rabbit experimentation was conducted at South Australian Health & Medical Research Institute Preclinical Imaging & Research Laboratories (SAHMRI-PIRL) at Gilles Plains, South Australia. Rabbit experimental protocols were approved by the SAHMRI Animal Ethics Committee (approval numbers SAM 399.19 and SAM-20-038).

Vaccine strain. The strain was based on the nonencapsulated Rx1 strain previously modified to delete autolysin (lytA) and attenuate pneumolysin (ply) genes (detailed in Babb et al. [18]), and to delete the pneumococcal surface antigen A (psaA) gene (detailed in David et al. [20]). The resulting vaccine...
strain Rx1 (ΔLytA, PdT, ΔPsA) is referred to as ‘GPN-002’ in this study. A virulence of GPN-002 was confirmed by intraperitoneal (IP) challenge of female Swiss mice at 7 weeks of age, purchased from University of Adelaide Laboratory Animal Services (LAS) facility and housed at the LAS facility for a week to acclimate. Mice were injected IP with live serotype 2 strain D39 (1 × 10^7 CFU/mouse) in phosphate-buffered saline (PBS) or live GPN-002 (1 × 10^6 CFU/mouse in PBS). Mice were monitored multiple times daily for development of clinical symptoms. Mice were euthanized when they became moribund in accordance with ethics approval S-2016-183. Weights were recorded daily for all mice for 2 weeks post-challenge (Fig. S1A).

**Vaccine manufacture and inactivation.** GPN-002 vaccine strain was statically grown in soytone media (Table S2). GPN-002 was first inoculated into soytone media to optical density at 600 nm (OD_{600}) = 0.05 in 50 mL final volume, and grown to OD_{600} = 0.5 at 37°C. This primary culture was inoculated into 450 mL of soytone to OD_{600} = 0.05 and grown again to OD_{600} = 0.5. 500 mL culture then sub-cultured into 4.5 L of soytone and grown to a final OD_{109} of 1.7. Cultures were immediately cooled on ice and centrifuged at 12,320 × g at 4°C. Cultures were washed twice in PBS, resuspended to a final concentration of 5 × 10^7 CFU/mL in PBS + 13% glycerol. Concentrated GPN-002 stocks were frozen at −80°C in 1.5 mL aliquots.

Frozen GPN-002 was inactivated with 16 kGy of gamma irradiation from a Cobalt-60 source at the Australian Nuclear Science and Technology Organization (ANSTO), Lucas Heights NSW, Australia. Samples were kept frozen on dry ice for the full irradiation treatment, and during storage and transport between facilities. Irradiation dose was selected based on prior work (20). D_{10} analysis (Fig. S1B) confirmed inactivation of GPN-002 from doses of 9 kGy onwards. To determine protein content, 16 kGy gamma-irradiated GPN-002 (referred to herein as Gamma-PN) was lysed with 1% sodium dodecyl sulfate (SDS) at 100°C for 5 min, and total protein quantified at 7.90 mg/mL using the DC protein assay kit (Bio-Rad, Protein Assay Dye Reagent Concentrate, no. 5000112) as per manufacturer’s instructions.

**Mouse immunizations.** Female Swiss mice at 4 to 5 weeks of age were purchased from ARC Animal Facility (WA, Australia), or University of Adelaide Laboratory Animal Services (LAS), then housed at the LAS facility in Adelaide for a week to acclimatize. Mice were injected IP with live serotype 2 strain D39 (1 × 10^8 CFU/mouse in PBS) at 7 weeks of age, purchased from Charles River (Wilmington, MA), then housed at the American Association for the Accreditation of Laboratory Animal Care (AAALAC)-accredited animal facility (WA, Australia), or University of Adelaide Laboratory Animal Services (LAS), then housed at the LAS facility in Adelaide for a week to acclimatize. Mice were injected IP with live serotype 2 strain D39 (1 × 10^8 CFU/mouse in PBS) for 10 min, then resuspended in PBS + 13% glycerol at OD_{600} = 2.0 and frozen at −80°C until use. Strains were resuspended at 1 × 10^8 CFU/mL in PBS immediately prior to use in binding assays. Next, 100 μL of bacteria were added to wells of a U-bottom 96-well tray, spun at 3,273 × g for 10 min to pellet, and washed 2× with PBS. Pellets were resuspended in 50 μL of murine or rabbit sera
diluted 1:200 in PBS + 1% bovine serum albumin (BSA). Serum samples were pooled in equal volumes within each vaccine group and heat-inactivated at 56°C for 30 min prior to use. Pellets were incubated in primary sera for 45 min on ice, then washed 3 × in PBS. Pellets were resuspended in 50 μL secondary antibody in PBS + 1% BSA, using Alexa-Fluor488-conjugated goat antimouse IgG (H+L) (Invitrogen, catalog no. A-1101, 1/500 dilution) or Alexa-Fluor488-conjugated donkey anti-rabbit IgG (Thermo Fisher, catalog no. A-21206; 1/1,000 dilution) to detect murine and rabbit primary sera, respectively. After 45 min on ice, pellets were washed 3 × in PBS and resuspended in 200 μL 2% paraformaldehyde (PFA; 0.2-μm filter sterilized) for acquisition using an Accuri Flow cytometer; 10,000 events were acquired per sample. PFA alone was used as a blank control to ensure the absence of non-Spn events (<100 events in 50 μL of PFA only control was required for each experiment to be considered valid). Gating strategy for IgG-positive events is shown in Fig. S2.

**Western blots.** Wild-type Spn isolates were grown as above and quantified using the DC protein assay kit prior to SDS-PAGE. Samples were diluted in milliQ water + 1x LUG buffer and boiled at 100°C for 5 min. Whole-cell lysates were loaded into duplicate wells on precast NuPAGE 4 to 12% Bis-Tris protein gels (Invitrogen, catalog no. NW04127) at 3.75 μg protein/well. Proteins were transferred to nitrocellulose membranes using the i blot gel transfer system (Invitrogen, catalog no. IB301002). Membranes were blocked in 2% skim milk buffer, sera from immunized or control animals were pooled and heat inactivated as described for the IgG binding assay, then diluted 1/1,000 (mouse) or 1/5,000 (rabbit) in 2% skim milk blocking buffer and used to probe the membranes. After overnight incubation at room temperature (RT) with orbital shaking, membranes were washed, and bound primary antibody was detected with Odyssey IRDye-800CW goat antimouse IgG (no. 926-32210) or Odyssey IRDye-680RD goat antirabbit IgG (no. 926-68073) for 1 h with shaking at RT. Membranes were washed in milliQ water prior to imaging with the Li-COR Odyssey Imaging System.

**Acute reactogenicity analysis.** Mice were immunized once in both quadriceps muscles with Gamma-PN, Gamma-PN + Alhydrogel, or PCV13 as described in Animal Immunizations. Control mice were mock immunized with PBS + Alhydrogel or received no treatment to indicate baseline status. Baseline controls were euthanized immediately, and both quadriceps muscles were excised. Tissues from treated animals were similarly harvested 6 to 7 h postimmunization, and each quadriceps muscle was processed immediately after harvest for cytokine analysis or histology. The right quadriceps muscle from each animal was rinsed in PBS and placed in bead tube with 1 mL PBS + protease inhibitor cocktail (Sigma, no. P8340). Tissues were homogenized for 3 × 30 s cycles at 5,000 rpm, then transferred to fresh 2-mL Eppendorf tubes and spun at 13,523 × g for 20 min at 4°C. Supernatants were transferred to a new tube and stored at −80°C until analysis. Muscle supernatant samples were analyzed by a multiplex murine cytokine and chemokine panel (Crux Biolab, Melbourne Australia) to detect G-CSF (CSF-3), GM-CSF, IL-1 beta, MCP-1 (CCL2), MCP-3 (CCL7), MIP-1 alpha (CCL3), MIP-1 beta (CCL4), and MIP-2 alpha (CXC2L2). The left quadriceps muscle from each animal was rinsed in PBS and placed in 20 mL of 10% neutral buffered formalin (100 mL 37% formaldehyde, 900 mL distilled water, 4 g monobasic sodium phosphate [NaH2PO4], 6.5 g dibasic sodium phosphate [Na2HPO4], pH adjusted to 6.8). Muscle tissues were fixed in this solution for 48 to 72 h at RT, then rinsed once in PBS and transferred to 25 mL of 70% ethanol (vol/vol in distilled water) for transport to Adelaide Histology Services (University of Adelaide AHMS, Adelaide, Australia). Fixed tissues were embedded in paraffin blocks, sectioned, and stained with hematoxylin and eosin for histological analysis. Slides were imaged and scored by Adelaide Microscopy Services (University of Adelaide AHMS, Adelaide, Australia).

**Live Spn challenge.** Spn strains D39 (serotype 2), ST232 (serotype 3), P9 (serotype 6A), and 22-A45 (serotype 22F, SSI 22F/2, lot 06-06-52, NSW Health Pathology Westmead) were grown in serum broth to OD560 = 0.2, then frozen at −80°C until the day of challenge. Mice were immunized as described earlier, then were in challenged with live Spn 2 weeks after the final immunization. All mice were first anaesthetized by IP injection of ketamine anesthetic (10% ketamine hydrochloride H2O, dosed at 10 mg/kg of animal body weight. Once anaesthetized, Spn inoculum containing 2 × 105 CFU (ST232) or 2 × 106 CFU (D39, P9, 22-A45) in 25 μL of PBS was administered through the nostrils. Mice were individually monitored to ensure regular breathing and recovery from anesthesia. For analysis of survival, mice were monitored multiple times daily for development of clinical symptoms for 2 to 3 weeks postchallenge and were humanely euthanized once moribund.

**Passive protection assay.** Pooled serum from rabbits immunized with Gamma-PN, Gamma-PN + Alhydrogel or prebleed serum was heat-inactivated at 56°C for 30 min. Pooled serum was mixed at a 1:10 dilution with Spn serotype 6A strain P9 (1 × 105 CFU/mL) and incubated for 30 min at 37°C to allow antibodies to bind bacteria. Then, 100 μL of serum-treated Spn was injected IP into 4 to 6-week-old female Swiss mice (1 × 104 CFU/mouse). All mice were monitored for 7 days postchallenge for clinical symptoms and overall survival.

**Protein array analysis.** Immune sera from Gamma-PN and Gamma-PN + Alhydrogel immunized mice or rabbits were pooled within each group in equal volumes. Sera from PBS mock-immunized mice were pooled as the mouse negative control, and prebleed sera from immunized rabbits were pooled as the rabbit negative control. Pooled sera were used in technical triplicate to probe a protein array containing 289 individual Spn proteins (61). Proteins were selected based on presence and conservation level in a panel of >600 Spn strains, and identification by Croucher et al. (61) as being recognized at significant levels by IgG present in human sera from healthy adults. Protein array analysis was performed as previously described by Schreig et al. (62) and Nakajima et al. (63). Briefly, the array was constructed using genes from Spn strain TIGR4 where proteins were expressed and tested for expression by Western blotting using antibodies against N-terminal polyhistidine (His) tags and printed onto nitrocellulose-coated glass AVID slides (Grace Bio-Labs) using an Omni Grid 100 microarray printer (Genomic Services (University of Adelaide AHMS, Adelaide, Australia)).
Data acquisition for all samples was performed on a BD LSR Fortessa X-20 cell sorter (FACS) buffer and incubated in sterile human sera (diluted 1/50 in FACS buffer) to block human Fc receptors. Cells were washed in FACS buffer, then incubated on ice for 30 min with either: antihuman CD35, anti-Annexin V antibody (BD Pharmingen, component no.51-65874X; diluted 1/20 in Annexin V binding buffer), or antihuman CD11b (final dilution 1/30), detailed in Table S1. Cells were washed in FACS buffer, then in PBS + 0.04% sodium azide before resuspension in 1% PFA. Data acquisition for all samples was performed on a BD LSR Fortessa X-20 flow cytometer. HL-60 differentiation was confirmed by flow cytometry, as described in Fig. S3-S5.

Spn strains for use in OPKA were grown as described for the IgG binding assay. Strains were diluted to 1 × 10^6 CFU/mL in opsonophagocytic buffer B (OBB) and kept on ice until use. Rabbit sera were heat-inactivated, serially diluted with OBB, and mixed with bacteria. Trays were incubated for 30 min at RT in room air on a miniorbital shaker (350 rpm). Baby rabbit complement (complement, Pel-Freez) and inactivated, serially diluted with OBB, and mixed with bacteria. Trays were incubated for 45 min at 37°C with 5% CO₂ on an orbital shaker (350 rpm). Opsonophagocytosis was stopped by placing the plates on ice for 20 min. Samples were plated on blood agar plates, with incubation overnight at 37°C, 5% CO₂, 30°C for serotype 3 to avoid overgrowth prior to CFU enumeration. OPKA titers were calculated using the Opsonophagocytosis result program (provided by Robert Burton, UAB). All sera were tested individually in the OPKA, except for the prebleed control samples which were pooled from all rabbits within a given immunization experiment. Rabbit sera from each immunization experiment were also tested in independent OPKA runs. This approach was required to save unnecessary use of animals (i.e., pilot immunization and OPKA experiment). Rabbit sera from each immunization experiment were also tested in independent OPKA runs. This approach was required to save unnecessary use of animals (i.e., pilot immunization and OPKA testing was conducted for efficacy confirmation prior to commencement of second immunization experiment).

OPKA third-party validation was performed in the New Vaccines Laboratory, Murdoch Children’s Research Institute, Melbourne, Australia as previously published (64). The method used was as specified above with the following alterations: pooled serum from rabbits immunized with Gamma-PN or PCV13 were used, with 007sp reference serum used as a positive control. S. pneumoniae strains TREP6A and TREP22F (BEI Resources) were used in this study. Samples were plated on THY agar and allowed to absorb into plate. Once plates were dry, they were covered with an overlay containing THY agar + triphenyl tetrazolium chloride (TTC). After overnight incubation colonies were enumerated using a ProtoCOL3 colony counter.

Statistical analyses. Quantitative results were expressed as mean ± SD. One-way ANOVA was used for comparison of data from 3 or more groups involving a single independent variable. Two-way ANOVA was used when data were grouped according to two independent variables. Tukey’s multiple-comparison test was used for post hoc analysis. For nonparametric data (determined using the D’Agostino & Pearson test and the Shapiro-Wilk test), the Mann-Whitney U-test was used. Survival percentages were analyzed by Fisher Exact test or Mantel-Cox test. All analyses were performed using GraphPad Prism, version 9.0.1 (GraphPad Software, La Jolla, USA). P-values <0.05 (95% confidence) were considered statistically significant.

Data availability. Biological data relating to this study have been deposited in the community-approved and cross-disciplinary public repository Zenodo, under the DOI 10.5281/zenodo.7074253. All deposited data is open access, in accordance with findable, accessible, interoperable, and reusable (FAIR) data principles.

SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

FIG S1, TIF file, 1.9 MB.
FIG S2, TIF file, 2.3 MB.
FIG S3, TIF file, 2.3 MB.
FIG S4, TIF file, 2.3 MB.
FIG S5, TIF file, 2.7 MB.
TABLE S1, DOCX file, 0.01 MB.
TABLE S2, DOCX file, 0.01 MB.
TABLE S3, DOCX file, 0.01 MB.
ACKNOWLEDGMENTS

We thank Jim Manavis and Adelaide University Microscopy (Adelaide, Australia) for assistance in histology sample preparation, staining, and imaging.

This work was supported by an Australian Institute of Nuclear Science and Engineering (AINSE) Research Award (ALNGRA15517; to M.A.); an Australian Postgraduate Award and GPN Vaccines Ltd. research sponsorship (to S.C.D.); National Health and Medical Research Council (NHMRC) Development Grant 1136903 (awarded to J.C.P., M.A., and T.R.H.), and NHMRC Investigator Grant 1174876 (awarded to J.C.P.). The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

M.A. is a Director of GPN Vaccines Ltd., J.C.P. is a Director and Chief Scientific Officer of GPN Vaccines Ltd., and T.R.H. is the Chief Executive Officer of GPN Vaccines Ltd. M.A., J.C.P., T.R.H., and S.C.D. hold an equity interest in GPN Vaccines Ltd. This does not alter adherence to policies on reporting and sharing of data, protocols, and materials.

REFERENCES

1. Torres A, Cilloniz C, Niederman MS, Menendez R, Chalmers JD, Wunderink RG, van der Poll T. 2021. Pneumonia. Nat Rev Dis Primers 7:25. https://doi.org/10.1038/s41572-021-00259-0.

2. Shafran N, Shafiran I, Ben-Zvi H, Sofer S, Sheena L, Krause I, Shlomi A, Goldberg E, Sklan EH. 2021. Secondary bacterial infection in COVID-19 patients is a stronger predictor for death compared to influenza patients. Sci Rep 11:12703. https://doi.org/10.1038/s41598-021-92220-0.

3. Ganarie F, Saad JS, McGee L, van Tonder AJ, Bentley SD, Lo SW, Gladstone RA, Turner P, Keenan JD, Breiman RF, Nahm MH. 2020. A new pneumococcal capsule type, 10D, is the 100th serotype and has a large cps fragment from an oral Streptococcus. mBio 11:e00937-20. https://doi.org/10.1128/mBio.00937-20.

4. Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LD, Zulz T, Hurlburt DA, Butler JC, Rudolph K, Parkinson A. 2007. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297: 1784–1792. https://doi.org/10.1001/jama.297.16.1784.

5. Flasche S, Van Hoek AJ, Sheasby E, Waught P, Andrews N, Sheppard C, George R, Miller E. 2011. Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study. PLoS Med 8:e1001017. https://doi.org/10.1371/journal.pmed.1001017.

6. Wijayasri S, Hillier K, Lim GH, Harris TM, Wilson SE, Deeks SL. 2019. The shift towards serotype-independent pneumococcal conjugate vaccine in Japan. J Infect Public Health 13:1094–1098. https://doi.org/10.1016/j.jiph.2019.04.012.

7. Richter SS, Diekema DJ, Heilmann KP, Dohrn CL, Riahi F, Doern GV. 2014. Serotype-independent pneumococcal colonization and invasive disease in Ontario, Canada, 2007–2017. PLoS One 14:e0226353. https://doi.org/10.1371/journal.pone.0226353.

8. Richter SS, Diekema DJ, Heilmann KP, Dohrn CL, Riahi F, Doern GV. 2014. Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States. Antimicrob Agents Chemother 58:6484–6489. https://doi.org/10.1128/AAC.03444-14.

9. Sheppard C, Fry NK, Musttagt S, Woodford N, Reynolds R, Janes R, Pike R, Hill R, Kimuli M, Stavres P, Dounith M, Harrison T, Livermore DM. 2016. Rise of multidrug-resistant non-vaccine type 15A Streptococcus pneumoniae in the United Kingdom, 2001 to 2014. Euro Surveill 21:30423.

10. Kawaguchiya M, Urushibara N, Aung MS, Ito M, Takahashi A, Habadera S, Kawaguchiya M. 2016. Intranasal vaccination with gamma-irradiated Streptococcus pneumoniae for the use as an immunogen. J Microbiol 56:579–585. https://doi.org/10.1007/s13295-016-08347-1.

11. Malley R, Rannard S, Alshari M. 2015. A new pneumococcal surface antigen A mutant whole-cell inactivated pneumococcal vaccine. J Microbiol 50:670–678. https://doi.org/10.1007/s13295-014-0344-4.

12. Ramos-Sevillano E, Ercoli G, Felgner P, Ramiro de Assis R, Nakajima R, Goldblatt D, Heyderman RS, Gordon SB, Ferreira DM, Brown JS. 2021. Pre-clinical development of virulence-attenuated Streptococcus pneumoniae strains able to enhance protective immunity against pneumococcal infection. J Med Microbiol 170:107233–107241. https://doi.org/10.1099/jmm.0.08641-18.

13. Wilson R, Cohen JM, Reglinski M, Jose RJ, Chan WY, Marshall H, de Vogel C, Gordon S, Goldblatt D, Petersen FC, Baxendale H, Brown JS. 2017. Naturally acquired human immunity to pneumococcus is dependent on antibody to protein antigens. PLoS Pathog 13:e1006137. https://doi.org/10.1371/journal.ppat.1006137.

14. Ng YH, Yeo D, Chan LK, Yau SW, Hui D, Lam KL. 2018. Gamma-irradiation of Streptococcus pneumoniae for the use as an immunogenic whole cell vaccine. J Microbiol 56:579–585. https://doi.org/10.1007/s13295-018-08347-1.
34. Lu Y-J, Leite L, Gonçalves VM, Dias WdO, Liberman C, Fratelli F, Alderson
33. Goldblatt D, Plikaytis BD, Akkoyunlu M, Antonello J, Ashton L, Blake M,
32. Paschall AV, Middleton DR, Avci FY. 2019. Opsonophagocytic killing assay
31. Rose CE, Romero-Steiner S, Burton RL, Carlone GM, Goldblatt D, Nahm
29. Romero-Steiner S, Libutti D, Pais LB, Dykes J, Anderson P, Whitin JC,
28. Matanock A, Lee G, Gierke R, Kobayashi M, Leidner A, Pilishvili T. 2019.
27. Lee H, Cha JH, Nahm MH, Burton RL, Kim KH. 2013. The 7-valent pneumo-
26. Grant LR, O
25. Ercoli G, Ramos-Sevillano E, Nakajima R, de Assis RR, Jasinskas A,
23. Goto N, Kato H, Maeyama J, Shibano M, Saito T, Yamaguchi J, Yoshihara S.
22. Goto N, Akama K. 1982. Histopathological studies of reactions in mice
Serotype-Independent
Streptococcus pneumoniae
Infect Dis 13:474. https://doi.org/10.1186/1471-2334-13-474
21. Rose CE, Burton RL, Ljutic B, M生产厂家, Ochs M, Messham B, Ming M, Dookie A, Harper K, Ausar SF. 2012.
20. Hansen B, Malyna P, Singh M, Sun Y, Srivastava I, Hog
19. Nelson AL, Roche AM, Gould JM, Chim K, Ratner AJ, Weiser JN. 2007. Capsule
18. Hijmans V, Brien KL, Goldblatt D. 2013. Establishment of a new human pneumococcal standard reference serum, J Virol
17. Ercoli G, Ramos-Sevillano E, Nakajima R, de Assis RR, Jasinskas A, Goldblatt D, Felgner P, Weckbecker G, Brown J. 2020. The in
16. Li Y, Weinberger DM, Thompson CM, Tzotziris K, Lipitch M. 2013. Surface
15. Lee H, Cha JH, Nahm MH, Burton RL, Kim KH. 2013. The 7-valent pneumococcal conjugate vaccine elicits cross-functional opsonophagocytic killing responses to Streptococcus pneumoniae serotype 6D in children. BMC Infect Dis 13:474. https://doi.org/10.1186/1471-2334-13-474
14. Rose CE, Burton RL, Ljutic B, M生产厂家, Ochs M, Messham B, Ming M, Dookie A, Harper K, Ausar SF. 2012.
13. Paschall AV, Middleton DR, Avci FY. 2019. Opsonophagocytic killing assay to assess immunological responses against bacterial pathogens. J Vis Exp 146:e59400.
12. Goldblatt D, Plikaytis BD, Akkoyunlu M, Antonello J, Ashto
11. Rose CE, Burton RL, Ljutic B, M生产厂家, Ochs M, Messham B, Ming M, Dookie A, Harper K, Ausar SF. 2012.
10. https://doi.org/10.1186/1476-8518-6.5.685
9. 2013. The 7-valent pneumococcal conjugate vaccine elicits cross-functional opsonophagocytic killing responses to Streptococcus pneumoniae serotype 6D in children. BMC Infect Dis 13:474. https://doi.org/10.1186/1471-2334-13-474
8. Lee H, Cha JH, Nahm MH, Burton RL, Kim KH. 2013. The 7-valent pneumococcal conjugate vaccine elicits cross-functional opsonophagocytic killing responses to Streptococcus pneumoniae serotype 6D in children. BMC Infect Dis 13:474. https://doi.org/10.1186/1471-2334-13-474
7. Lee H, Cha JH, Nahm MH, Burton RL, Kim KH. 2013. The 7-valent pneumococcal conjugate vaccine elicits cross-functional opsonophagocytic killing responses to Streptococcus pneumoniae serotype 6D in children. BMC Infect Dis 13:474. https://doi.org/10.1186/1471-2334-13-474
6. Grant LR, O’Brien SE, Burbridge P, Haston M, Zancolli M, Cowell L, Johnson M, Weatherholtz RC, Reid R, Santosham M, O’Brien KL, Goldblatt D. 2013. Comparative immunogenicity of 7 and 13-valent pneumococcal conjugate vaccines and the development of functional antibodies to cross-reactive serotypes. PLoS One 8:e74906. https://doi.org/10.1371/journal.pone.0074906
5. 2019. Opsonophagocytic killing assay and the influence of functional antibodies to cross-reactive serotypes. PLoS One 8:e74906. https://doi.org/10.1371/journal.pone.0074906
4. Lee H, Cha JH, Nahm MH, Burton RL, Kim KH. 2013. The 7-valent pneumococcal conjugate vaccine elicits cross-functional opsonophagocytic killing responses to Streptococcus pneumoniae serotype 6D in children. BMC Infect Dis 13:474. https://doi.org/10.1186/1471-2334-13-474
3. Lee H, Cha JH, Nahm MH, Burton RL, Kim KH. 2013. The 7-valent pneumococcal conjugate vaccine elicits cross-functional opsonophagocytic killing responses to Streptococcus pneumoniae serotype 6D in children. BMC Infect Dis 13:474. https://doi.org/10.1186/1471-2334-13-474
2. Lee H, Cha JH, Nahm MH, Burton RL, Kim KH. 2013. The 7-valent pneumococcal conjugate vaccine elicits cross-functional opsonophagocytic killing responses to Streptococcus pneumoniae serotype 6D in children. BMC Infect Dis 13:474. https://doi.org/10.1186/1471-2334-13-474
1. Lee H, Cha JH, Nahm MH, Burton RL, Kim KH. 2013. The 7-valent pneumococcal conjugate vaccine elicits cross-functional opsonophagocytic killing responses to Streptococcus pneumoniae serotype 6D in children. BMC Infect Dis 13:474. https://doi.org/10.1186/1471-2334-13-474
Serotype-Independent
Streptococcus pneumoniae
Infect Dis 13:474. https://doi.org/10.1186/1471-2334-13-474
57. David SC, Lau J, Singleton EV, Babb R, Davies J, Hirst TR, McColl SR, Paton JC, Alsharifi M. 2017. The effect of gamma-irradiation conditions on the immunogenicity of whole-inactivated Influenza A virus vaccine. Vaccine 35:1071–1079. https://doi.org/10.1016/j.vaccine.2016.12.044.

58. Rivera-Hernandez T, Rhyme MS, Cork AJ, Jones S, Segui-Perez C, Brunner L, Richter J, Petrovsky N, Lawrenz M, Goldblatt D, Collin N, Walker MJ. 2020. Vaccine-induced Th1-type response protects against invasive group A streptococcus infection in the absence of opsonizing antibodies. mBio 11:e00122-20. https://doi.org/10.1128/mBio.00122-20.

59. Campos IB, Herd M, Moffitt KL, Lu YJ, Darrieux M, Malley R, Leite LC, Goncalves VM. 2017. IL-17A and complement contribute to killing of pneumococci following immunization with a pneumococcal whole cell vaccine. Vaccine 35:1306–1315. https://doi.org/10.1016/j.vaccine.2017.01.030.

60. Keech CA, Morrison R, Anderson P, Tate A, Flores J, Goldblatt D, Briles D, Hural J, Malley R, Alderson MR. 2020. A phase 1 randomized, placebo-controlled, observer-blinded trial to evaluate the safety and immunogenicity of inactivated Streptococcus pneumoniae whole-cell vaccine in adults. Pediatr Infect Dis J 39:345–351. https://doi.org/10.1097/INF.0000000000002567.

61. Croucher NJ, Campo JJ, Le TQ, Liang X, Bentley SD, Hanage WP, Lipsitch M. 2017. Diverse evolutionary patterns of pneumococcal antigens identified by pan-genome-wide immunological screening. Proc Natl Acad Sci U S A 114:E357–E366. https://doi.org/10.1073/pnas.1613937114.

62. Schreeg ME, Marr HS, Tarigo JL, Sherrill MK, Outi HK, Scholl EH, Bird DM, Vigil A, Hung C, Nakajima R, Liang L, Trieu A, Doolan DL, Thomas JE, Levy MG, Reichard MV, Felghner PL, Cohn LA, Birkenheuer AJ. 2018. Identification of Cyttauxzoon felis antigens via protein microarray and assessment of expression library immunization against cytauxzoonosis. Clin Proteomics 15:44. https://doi.org/10.1186/s12014-018-9218-9.

63. Nakajima R, Supnet M, Jasinskas A, Jain A, Taghavian O, Obiero J, Milton DK, Chen WH, Grantham M, Webby R, Krammer F, Carter D, Felghner PL, Davies DH. 2018. Protein microarray analysis of the specificity and cross-reactivity of influenza virus hemagglutinin-specific antibodies. mSphere 3:e00592-18. https://doi.org/10.1128/mSphere.00592-18.

64. Licciardi PV, Temple B, Dai VTT, Toan NT, Uyen D, Nguyen CD, Phan TV, Bright K, Marimla RA, Balloch A, Huu TN, Mulholland K. 2021. Immunogenicity of alternative ten-valent pneumococcal conjugate vaccine schedules in infants in Ho Chi Minh City, Vietnam: results from a single-blind, parallel-group, open-label, randomised, controlled trial. Lancet Infect Dis 21:1415–1428. https://doi.org/10.1016/S1473-3099(20)30775-1.